U.S. Personalized Diabetes Care Devices Market

Market Outlook

By 2035, the U.S. Personalized Diabetes Care Devices Market is expected to reach approximately USD 36.40 billion, expanding at a CAGR of 12.00% during the forecast period 2026–2035. The market is estimated at USD 11.72 billion in 2025, following expansion from approximately USD 7.44 billion in 2021, USD 8.27 billion in 2022, USD 9.30 billion in 2023, and USD 10.47 billion in 2024. Historical analysis covers 2021–2024, with all market values expressed in USD billions.

For the purpose of this report, personalized diabetes care devices include regulated and clinically oriented hardware systems that use patient-specific glucose information, insulin requirements, behavioral patterns, physiological trends, or adaptive algorithms to individualize diabetes monitoring or therapy. The scope includes continuous glucose monitoring systems, automated insulin delivery platforms, connected insulin pumps, smart insulin pens and injection systems, connected blood glucose meters, implantable glucose sensors, interoperable diabetes devices, and device-integrated decision-support technologies. Pharmaceutical insulin revenue, general-purpose consumer wearables, and standalone digital health applications without a meaningful medical-device component are excluded.

The U.S. opportunity is being reshaped by the transition from periodic glucose measurement toward continuous, individualized disease management. Approximately 40 million Americans are living with diagnosed or undiagnosed diabetes, creating an exceptionally large clinical base for technologies that can improve glucose visibility, reduce treatment burden, prevent severe hypoglycemia, increase time in range, and support more precise medication decisions.

Personalization is becoming particularly important because diabetes management is inherently heterogeneous. Two patients with similar HbA1c values may have materially different glucose variability, nocturnal patterns, post-meal excursions, insulin sensitivity, adherence behavior, activity levels, and risk of hypoglycemia. The next generation of devices therefore competes less on the ability to capture a glucose value and more on the ability to translate continuous patient-level information into actionable therapeutic decisions.

This shift is increasing the strategic value of continuous sensing, algorithm-driven insulin delivery, interoperability, cloud connectivity, simplified onboarding, predictive alerts, and patient-specific dosing logic. The strongest growth is expected in continuous glucose monitoring and automated insulin delivery, particularly as technologies historically associated with intensively managed type 1 diabetes expand into insulin-treated type 2 diabetes and selected non-insulin populations.

The commercial model is also changing. Manufacturers are increasingly building recurring-revenue ecosystems around sensors, disposable pods, infusion sets, transmitters, consumables, mobile connectivity, analytics, and clinical data platforms. Consequently, market leadership through 2035 will depend not only on device accuracy but also on user retention, payer access, interoperability, ease of use, supply continuity, clinician workflow compatibility, and the ability to demonstrate measurable improvement in glycemic outcomes.

Introduction

According to the U.S. Personalized Diabetes Care Devices Market Report, personalization is becoming one of the defining principles of modern diabetes technology. The traditional diabetes device model depended heavily on episodic fingerstick testing, manually calculated insulin doses, fixed treatment routines, and retrospective physician review. The emerging model continuously captures patient data, interprets patterns, adapts therapy, and creates a feedback loop between the patient, device, caregiver, and clinician.

The clinical need is substantial. Diabetes affects roughly one in eight Americans, and more than 29 million people have diagnosed disease. The U.S. also has more than 115 million adults with prediabetes, creating an adjacent population that may progressively increase demand for metabolic monitoring and earlier intervention. Diagnosed diabetes alone generates hundreds of billions of dollars in direct and indirect economic costs, making technologies that can reduce complications, hospital utilization, severe hypoglycemia, and treatment inefficiency strategically relevant to payers and health systems.

The market is therefore moving beyond the conventional distinction between glucose meters and insulin pumps. Personalized diabetes care increasingly operates as an interoperable ecosystem. A CGM can continuously characterize glucose behavior; an algorithm can interpret the data; an insulin pump can automatically modify delivery; a connected pen can record dosing behavior; and a remote clinical platform can help care teams identify patients whose therapy requires intervention.

This creates a broader commercial opportunity than standalone device replacement. Manufacturers are increasingly competing for control of the patient’s daily diabetes workflow. Companies able to connect sensing, delivery, dosing intelligence, alerts, patient engagement, and clinical review can generate deeper customer relationships and higher recurring revenue than companies supplying isolated hardware.

U.S. market growth will also be affected by reimbursement design. Expansion of Medicare CGM eligibility has widened access beyond historically narrow intensive-insulin criteria, while commercial insurers increasingly evaluate diabetes technology using outcomes such as HbA1c reduction, time in range, hypoglycemia prevention, adherence, emergency utilization, and total cost of care. As evidence improves, personalized device adoption is expected to penetrate a progressively broader diabetes population.

Key Market Drivers: What’s Fueling the U.S. Personalized Diabetes Care Devices Market Boom?

The first major driver is the scale and complexity of the U.S. diabetes population. Approximately 40.1 million Americans were estimated to have diagnosed or undiagnosed diabetes in 2023. More importantly from a device-market perspective, these patients do not represent a uniform treatment population. Insulin dependence, glucose variability, comorbid obesity, kidney disease, cardiovascular risk, age, dexterity, cognitive ability, insurance status, and digital literacy all influence which device delivers the greatest clinical value. Personalized technologies can address this heterogeneity more effectively than one-size-fits-all monitoring.

A second major driver is the structural migration from episodic glucose measurement to continuous sensing. Fingerstick blood glucose monitoring remains clinically relevant and highly accessible, but CGM provides a substantially richer dataset because it reveals glucose direction, variability, nocturnal behavior, post-prandial response, and time spent above or below target ranges. This allows therapy to become pattern-driven rather than value-driven. As sensor duration increases and device size, calibration requirements, onboarding complexity, and acquisition barriers decrease, CGM is becoming the central data layer of personalized diabetes management.

The expansion of CGM beyond traditional type 1 diabetes is especially important. Broader Medicare coverage, growing commercial payer acceptance, and regulatory expansion into non-insulin-treated populations increase the addressable market. OTC CGM availability further changes the access model by reducing dependence on conventional specialist prescribing pathways for eligible users. This could accelerate adoption among people with type 2 diabetes who historically relied on periodic HbA1c testing or intermittent fingersticks.

A third driver is automated insulin delivery. AID systems use CGM information and algorithmic decision-making to increase, reduce, suspend, or otherwise modify insulin delivery based on evolving patient needs. The clinical proposition is compelling because insulin requirements can change by time of day, food intake, illness, hormonal status, activity, sleep, and previous insulin exposure. Automated systems can respond to these changes more consistently than a fixed basal schedule.

Expansion of AID into type 2 diabetes significantly increases the long-term market opportunity. Type 2 diabetes represents the overwhelming majority of U.S. diabetes cases, and a meaningful subgroup eventually requires insulin. Regulatory decisions allowing automated systems to serve insulin-requiring adults with type 2 diabetes create a new growth cycle for pumps, pods, compatible CGMs, infusion supplies, and algorithm-enabled controllers.

A fourth driver is the need to reduce the cognitive burden of diabetes. Advanced diabetes management can require hundreds of small decisions related to meals, insulin timing, carbohydrate estimates, exercise, correction dosing, alarms, device changes, and glucose trends. Manufacturers are increasingly designing technology around reducing these daily decisions. Automated correction, simplified meal announcements, predictive alerts, personalized targets, longer sensor wear, tubeless delivery, smartphone control, and integrated dosing records all address treatment fatigue.

A fifth driver is the economics of avoidable complications. Diagnosed diabetes generates an economic burden exceeding USD 400 billion annually in the United States. Severe hypoglycemia, diabetic ketoacidosis, cardiovascular disease, kidney failure, neuropathy, retinopathy, amputations, emergency visits, and hospitalizations add substantial downstream expenditure. Personalized devices gain economic relevance when they help prevent high-cost events rather than simply improve a laboratory value.

A sixth driver is the expansion of remote and virtual diabetes care. Endocrinology supply is unevenly distributed across the U.S., particularly in rural and underserved markets. Connected devices allow glucose information, dosing behavior, and treatment trends to be reviewed without requiring every interaction to occur inside a clinic. This increases the potential productivity of endocrinologists, certified diabetes care and education specialists, pharmacists, primary care physicians, and virtual diabetes-management programs.

A seventh driver is interoperability. The market is moving toward modular systems in which consumers and clinicians may be able to combine compatible sensors, pumps, algorithms, smartphones, and data-management platforms. Interoperability increases device choice and reduces dependence on completely closed proprietary ecosystems. It also intensifies competitive pressure because the manufacturer controlling the most clinically valuable component may not necessarily control every element of the system.

An eighth driver is consumerization without complete separation from clinical care. Smaller sensors, smartphone interfaces, discreet pumps, wearable form factors, over-the-counter access, simpler insertion, and real-time behavioral insights increasingly resemble consumer technology experiences. However, unlike general wellness devices, diabetes technologies influence medication and potentially life-critical treatment decisions. The commercial winners will therefore be companies capable of combining consumer-grade usability with medical-grade reliability, cybersecurity, accuracy, and regulatory discipline.

Innovation in Focus: How Manufacturers Are Raising the Bar?

Innovation in personalized diabetes devices is increasingly centered on reducing patient effort while increasing the sophistication of background decision-making. The most advanced products are designed to make diabetes technology less visible in the user’s daily life.

CGM innovation is moving toward longer sensor wear, smaller form factors, simpler insertion, reduced calibration, faster warm-up, stronger connectivity, improved accuracy, and broader patient eligibility. Fifteen-day disposable sensors and 365-day implantable systems illustrate how manufacturers are approaching the same personalization challenge differently. Disposable CGM emphasizes convenience and easy replacement, while implantable CGM seeks to reduce repeated sensor insertion and long-term device-management burden.

Automated insulin delivery represents the most important convergence of personalization and therapeutic hardware. Algorithms increasingly learn or adapt to individual insulin requirements and use continuous glucose information to modify delivery. Technology development is moving toward fewer manual inputs, better meal handling, more personalized glucose targets, improved exercise management, and enhanced protection against hypoglycemia.

The commercial direction is also moving from tightly coupled proprietary systems toward greater interoperability. Sensor manufacturers are establishing integrations with insulin-delivery companies, while pump developers increasingly support more than one CGM ecosystem. This reduces the friction associated with switching technologies and could accelerate innovation cycles because a manufacturer can improve one layer of the system without rebuilding the entire diabetes platform.

Smart injection technologies represent another innovation opportunity. Millions of Americans continue to use multiple daily injections and may not want or qualify for pump therapy. Connected pens, reusable smart pens, pen-cap technologies, dose-memory features, and injection-tracking systems can capture missing information around insulin timing and quantity. When paired with glucose information, these systems can support more individualized recommendations while maintaining the familiarity of injection-based treatment.

Artificial intelligence and predictive analytics are emerging as additional differentiation layers. The highest-value applications are likely to involve risk prediction, therapy prioritization, pattern detection, adherence identification, and clinician workflow triage rather than generic patient-facing recommendations. Health systems managing thousands of people with diabetes need technology capable of identifying the small percentage of patients who require immediate intervention.

Segmentation Insights

The U.S. Personalized Diabetes Care Devices Market is segmented on the basis of product category, application, end user, technology type, and region. These five segmentation dimensions capture how device economics differ by hardware architecture, patient need, clinical setting, personalization mechanism, and geography.

By Product Category

Continuous Glucose Monitoring and Personalized Biosensor Systems

Continuous glucose monitoring represents the largest product category, accounting for an estimated USD 5.58 billion of the U.S. personalized diabetes care device market in 2025. The segment includes disposable real-time CGM sensors, flash or intermittently scanned systems, transmitters, receivers, implantable sensors, and connected biosensing components.

The category is benefiting from broader insurance coverage, longer wear duration, smartphone integration, improved accuracy, direct-to-consumer awareness, and expansion beyond intensively managed type 1 diabetes. CGM also has unusually attractive recurring economics because sensor replacement generates repeat revenue while accumulated glucose data increases user dependence on the broader platform.

Personalization occurs through trend analysis, customizable alerts, time-in-range measurement, glucose-pattern recognition, caregiver sharing, and integration with insulin-delivery algorithms. Through 2035, CGM is expected to remain the foundational technology layer for personalized diabetes management.

Automated Insulin Delivery Systems and Connected Insulin Pumps

Automated and connected insulin-delivery systems represented approximately USD 3.52 billion in 2025. The category includes tubed insulin pumps, tubeless patch pumps, alternate-controller-enabled pumps, interoperable pumps, disposable pods, associated infusion sets, controllers, and algorithm-linked delivery systems.

Growth is being driven by more compact hardware, smartphone control, tubeless designs, adaptive algorithms, reduced manual dosing burden, and expansion into insulin-requiring type 2 diabetes. Recurring revenue from pods, cartridges, and infusion supplies creates particularly attractive lifetime economics.

AID is likely to be one of the fastest-growing categories through 2035 as the clinical conversation shifts from whether automated delivery works to which patient groups can benefit from it economically and safely.

Smart Insulin Pens and Connected Injection Systems

Smart insulin pens and connected injection technologies represented an estimated USD 0.88 billion in 2025. These devices address patients who use injections but need more dosing intelligence than conventional disposable pens provide.

Important functionality includes dose recording, insulin-on-board calculation, missed-dose alerts, temperature monitoring, timing information, integration with CGM data, and digital dose history. This category occupies a strategically important position between conventional insulin pens and pumps.

Its addressable population is large because multiple daily injection therapy remains common. Successful products must minimize setup complexity and deliver meaningful clinical value without requiring the user to adopt a completely different insulin-delivery behavior.

Connected Blood Glucose Monitoring Systems

Connected blood glucose monitoring generated approximately USD 1.12 billion in 2025 within the personalized-device scope. The segment includes Bluetooth-enabled glucose meters, connected test-strip ecosystems, cellular-enabled monitoring devices, and systems that automatically transmit readings to mobile applications or care-management platforms.

Although conventional blood glucose monitoring is mature, connected BGM remains important for patients who cannot access CGM, prefer intermittent testing, have limited insurance coverage, or require confirmatory measurements. The personalization opportunity comes from automated data capture, pattern recognition, medication logs, coaching integration, and remote clinician visibility.

Pricing pressure will remain higher than in CGM, but the large installed base gives connected BGM strategic relevance in value-oriented diabetes programs.

Implantable and Adjunct Personalized Diabetes Devices

Implantable and adjunct systems represented approximately USD 0.62 billion in 2025. This category includes long-duration implantable glucose sensors, specialized wearable adjuncts, connectivity accessories, and emerging multi-parameter devices that support individualized diabetes management.

The segment is smaller but strategically important because it addresses specific patient preferences that disposable sensors and conventional pumps may not solve. One-year implantable sensing demonstrates the potential for differentiated device architectures built around reduced insertion frequency and long-term continuity.

By Application

Type 1 Diabetes Management

Type 1 diabetes remains the most technologically intensive application for personalized diabetes devices. More than two million Americans are estimated to have diagnosed type 1 diabetes, including a substantial pediatric population. Because endogenous insulin production is severely impaired, continuous glucose monitoring, pump therapy, automated insulin delivery, ketone awareness, and hypoglycemia prevention have unusually high clinical value.

Type 1 diabetes will continue to account for disproportionate device spending per patient even as type 2 diabetes becomes the larger incremental growth opportunity. Adoption is strongest among insured populations with access to endocrinology and diabetes education, although simplified technologies are expanding use outside highly specialized centers.

Insulin-Requiring Type 2 Diabetes

Insulin-treated type 2 diabetes is expected to become the most important incremental application through 2035. Historically, many patients with type 2 diabetes used injections and fingerstick monitoring even when their treatment complexity approached that of type 1 diabetes.

Broader CGM access and the extension of automated insulin-delivery technologies into type 2 diabetes materially expand the addressable market. Device companies that can demonstrate simpler onboarding, lower training requirements, reduced hypoglycemia, improved HbA1c, and sustainable payer economics are positioned to capture this opportunity.

Non-Insulin-Treated Type 2 Diabetes

Non-insulin-treated type 2 diabetes represents an emerging personalization market, driven particularly by CGM. These patients may use oral medications, injectable non-insulin therapies, diet, physical activity, or combinations of treatments. Continuous glucose data can reveal individual responses to meals, exercise, sleep, stress, and medication timing.

The challenge is demonstrating sustained clinical and economic value beyond short-term behavioral engagement. OTC access lowers one barrier, but durable adoption will depend on whether personalized glucose information produces measurable long-term improvement.

Gestational and Pregnancy-Associated Diabetes Management

Pregnancy creates a high-acuity use case because glycemic targets are tighter and poor control can affect maternal and fetal outcomes. CGM, connected BGM, remote data review, and precise insulin delivery can support women requiring intensive monitoring.

This remains a smaller revenue segment than type 1 or type 2 diabetes, but per-patient monitoring intensity can be substantial. Integration with obstetric and maternal-fetal medicine workflows will determine adoption.

Secondary, Complex and High-Risk Diabetes Management

Patients with steroid-induced diabetes, pancreatic disease, recurrent severe hypoglycemia, advanced kidney disease, complex comorbidity, or major glucose variability can require highly individualized monitoring. These populations are smaller but often consume disproportionate clinical resources.

Personalized devices can support earlier detection of instability and give multidisciplinary teams better information for treatment modification. Device selection in these patients tends to be evidence-driven and strongly influenced by specialist judgment.

By End User

Patients and Home Users

Home users represent the largest end-user category because personalized diabetes technology is fundamentally designed around continuous self-management. Patients directly interact with sensors, pumps, smart pens, meters, mobile applications, receivers, and alerts throughout the day.

Purchasing decisions are influenced by insurance coverage, out-of-pocket cost, sensor wear duration, insertion comfort, device size, alarm burden, smartphone compatibility, discretion, customer service, pharmacy versus DME access, and perceived impact on daily life. Patient retention is therefore as strategically important as initial prescription growth.

Endocrinology and Diabetes Specialty Clinics

Endocrinology practices are major clinical gatekeepers for high-complexity personalized devices. They initiate pump therapy, interpret CGM data, manage AID settings, support difficult insulin regimens, and train patients in advanced technology.

The major workflow challenge is data volume. Clinics increasingly prefer standardized reports, remote upload capability, actionable alerts, interoperability, and simplified onboarding. Manufacturers that reduce staff burden can gain advantages even when competing products have similar clinical specifications.

Hospitals and Integrated Health Systems

Hospitals and integrated delivery networks influence device access through formulary decisions, inpatient-to-outpatient transitions, contracting, population-health programs, and specialist networks. Large systems may standardize diabetes technologies to reduce training complexity and improve data integration.

Health-system interest is increasingly tied to preventing readmissions, improving discharge management, supporting high-risk populations, and connecting outpatient diabetes data to broader chronic-disease programs.

Primary Care and Multispecialty Practices

Primary care is becoming increasingly important as personalized diabetes technology expands beyond traditional type 1 populations. The U.S. endocrinology workforce cannot independently manage every patient who could benefit from CGM or connected monitoring.

Devices that are easier to prescribe, initiate, interpret, and maintain are therefore likely to penetrate primary care more effectively. Automated interpretation and concise clinical reports will be important because primary care physicians typically have less time for detailed device-data review.

Remote Diabetes Management and Home Healthcare Providers

Virtual diabetes programs, home-health organizations, payer-sponsored disease-management platforms, and remotely staffed clinical programs represent a growing end-user group. Their economic model depends on identifying deteriorating patients before complications require high-cost care.

Connected devices give these organizations a continuous data stream that can support escalation protocols, medication adjustment, coaching, adherence management, and risk stratification.

By Technology Type

Real-Time Continuous Glucose Monitoring

Real-time CGM is the dominant personalization technology because it continuously converts physiological glucose information into immediate feedback. Predictive alerts, customizable thresholds, caregiver sharing, and automatic data transmission make the technology particularly valuable for high-risk insulin users.

Longer sensor duration and simpler insertion will continue to increase adoption.

Intermittently Scanned and Consumer-Accessible Glucose Sensing

Intermittently scanned systems and newer consumer-accessible glucose sensors expand personalization to populations that may not require intensive real-time alerting. Their commercial strength is accessibility, user simplicity, and lower friction.

The boundary between clinical diabetes monitoring and metabolic self-management is expected to become increasingly important as manufacturers target patients earlier in the disease continuum.

Automated and Adaptive Insulin-Control Technology

Adaptive insulin-control technology represents the highest-value personalization layer because device output directly changes therapy. Algorithms continuously evaluate glucose direction, insulin exposure, and individualized treatment parameters.

Future differentiation will come from automation quality, meal handling, exercise management, personalization of targets, reduced setup burden, and interoperability with multiple sensors and pumps.

Connected Injection and Dose-Tracking Technology

Connected pens, smart caps, dosing accessories, and injection-tracking technologies digitize a treatment pathway that traditionally generated little usable data. These technologies can identify missed injections, duplicate dosing, timing problems, and possible relationships between dose behavior and glucose excursions.

The category has strong potential among patients who want personalization without transitioning to pump therapy.

AI-Enabled, Predictive and Interoperable Device Ecosystems

AI-enabled device ecosystems are becoming an important competitive layer. Their value lies in turning large volumes of glucose and dosing information into prioritized clinical action.

The most commercially successful systems are likely to focus on specific measurable problems such as predicting hypoglycemia, recognizing persistent post-meal patterns, identifying non-adherence, optimizing device settings, or prioritizing patients for clinician review.

Regional Insights: Where the Market is Growing Fastest

The U.S. Personalized Diabetes Care Devices Market is geographically segmented into the South, West, Northeast, and Midwest. Regional performance differs materially because diabetes prevalence, population scale, age distribution, insurance coverage, endocrinologist availability, technology adoption, health-system concentration, pharmacy access, rurality, and socioeconomic conditions vary across the country.

The South is estimated to represent the largest market in 2025, while the West is projected to generate the fastest CAGR through 2035. The Northeast remains an important premium-technology and academic adoption market, while the Midwest combines substantial diabetes burden with strong integrated health-system purchasing power.

South

The South represented an estimated USD 4.45 billion in 2025, making it the largest regional market. At the modeled trajectory, the region could reach approximately USD 13.25 billion by 2035, representing growth of roughly 11.5% annually.

The region includes Delaware, Florida, Georgia, Maryland, North Carolina, South Carolina, Virginia, West Virginia, Alabama, Kentucky, Mississippi, Tennessee, Arkansas, Louisiana, Oklahoma, and Texas, with the District of Columbia also included in the Census South regional framework.

The South combines three commercially significant characteristics: a large population base, elevated diabetes prevalence in many states, and significant inequality in access to specialty diabetes care. National surveillance consistently shows some of the highest concentrations of diagnosed diabetes in the Southeast. This creates strong clinical demand but also means that premium technology adoption cannot be evaluated solely through disease burden.

Texas is the largest strategic state opportunity in the region. Houston, Dallas-Fort Worth, Austin, and San Antonio contain large health systems, endocrinology networks, academic institutions, employer-insured populations, and pediatric diabetes programs. Texas also has substantial rural geography, creating an opportunity for remote monitoring and devices that can be initiated and managed outside specialist centers.

Florida is another critical market because of its large older population and extensive Medicare exposure. CGM reimbursement expansion is particularly meaningful in this environment. Florida combines large primary-care networks, Medicare Advantage penetration, high diabetes prevalence, and significant demand for home-based chronic-care technologies.

Georgia, North Carolina, Tennessee, and Virginia are attractive growth markets due to expanding metropolitan populations, major health systems, increasing ambulatory care infrastructure, and established academic diabetes programs. North Carolina’s research ecosystem and Virginia’s dense integrated-care networks make both states important for technology adoption beyond conventional endocrinology.

Mississippi, Alabama, Louisiana, Arkansas, Kentucky, and West Virginia have particularly high diabetes and obesity burdens in many communities. Their market opportunity is substantial but structurally different from affluent metropolitan areas. Affordability, Medicaid policy, pharmacy distribution, patient training, cellular connectivity, and rural clinician availability can materially affect adoption. Manufacturers pursuing these states need simplified reimbursement support and scalable education models rather than relying exclusively on specialist-led premium-device channels.

Oklahoma and South Carolina provide additional growth opportunities through diabetes prevalence, expanding regional health systems, and increasing demand for remote management. Maryland and Delaware benefit from comparatively dense healthcare infrastructure and proximity to major Mid-Atlantic academic systems.

Through 2035, the South is expected to remain the largest personalized diabetes-device market. The strongest commercial opportunities will come from broadening CGM access, type 2 automated insulin delivery, Medicare populations, pharmacy-channel distribution, remote care, and products designed for lower clinical-workflow burden.

West

The West represented approximately USD 2.72 billion in 2025 and is forecast to reach about USD 9.45 billion by 2035, implying an estimated CAGR of approximately 13.3%, the fastest among the four regions.

The region includes California, Oregon, Washington, Alaska, Hawaii, Arizona, Colorado, Idaho, Montana, Nevada, New Mexico, Utah, and Wyoming.

California is the anchor market and one of the most important personalized diabetes technology markets in the country. The state combines a very large population, sophisticated academic health systems, strong digital-health adoption, major managed-care organizations, technology-oriented consumers, venture capital activity, and proximity to diabetes-device innovators.

California is especially attractive for CGM, algorithm-enabled monitoring, interoperability, consumer-accessible biosensors, and hybrid virtual-care models. Large integrated systems also create opportunities for enterprise deployment when manufacturers can demonstrate population-level outcomes.

Washington and Oregon have strong connected-care adoption and relatively sophisticated health-system technology environments. Their provider networks are well suited to remote diabetes management, integrated CGM review, and patient-facing digital workflows.

Arizona and Nevada are high-growth markets because rapid population expansion and large older populations increase diabetes-management demand. These states are important for Medicare-oriented CGM adoption and scalable chronic-care programs.

Colorado and Utah combine comparatively technology-oriented populations with advanced integrated delivery networks and growing diabetes specialty capacity. Their markets are attractive for newer insulin-delivery systems, interoperable platforms, and remote monitoring.

New Mexico presents a different commercial profile because diabetes burden is substantial in several populations while access can be constrained by geography and clinician availability. Devices that support remote care and simplified patient self-management may therefore have greater value than solutions dependent on frequent in-person specialty visits.

Idaho, Montana, Wyoming, and Alaska are smaller device markets by absolute revenue but strategically relevant for tele-endocrinology, connected monitoring, and rural access. Hawaii has a smaller population base but meaningful diabetes burden within several communities and a geographically fragmented care-delivery environment.

The West is expected to gain national market share through 2035 because personalized diabetes care increasingly resembles the region’s strengths: connected, software-assisted, consumer-friendly, data-intensive, and remotely managed healthcare.

Northeast

The Northeast accounted for an estimated USD 2.45 billion in 2025 and is projected to reach approximately USD 7.35 billion by 2035, representing growth of roughly 11.6% annually.

The region includes Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, Vermont, New Jersey, New York, and Pennsylvania.

The Northeast is one of the highest-value regions for advanced diabetes technology because of its concentration of academic medical centers, endocrinologists, clinical research programs, affluent commercially insured populations, major integrated health systems, and sophisticated pediatric diabetes services.

New York is the region’s largest state market. New York City provides one of the country’s densest specialty-care environments, while upstate areas create a separate need for remote access and distributed diabetes management. Large health systems can influence formulary access and technology standardization across substantial patient populations.

Massachusetts is disproportionately important relative to its population because of its academic medicine, biotechnology, medtech, clinical research, and digital health ecosystem. The state is an influential early-evaluation market for emerging CGM, AID, and connected diabetes technologies.

Pennsylvania and New Jersey provide large commercially relevant patient pools with extensive hospital and specialist networks. Both states are attractive for pharmacy-based CGM distribution, health-system contracting, and employer-insured diabetes management.

Connecticut and Rhode Island have comparatively compact healthcare markets that support coordinated specialist networks. Maine, Vermont, and New Hampshire have smaller populations but meaningful opportunities in older adults, rural communities, and remote diabetes care.

The Northeast is unlikely to match the West’s percentage growth because it is already a mature premium-technology market. However, it will remain particularly important for clinical evidence generation, specialist influence, early adoption, pediatric diabetes technology, and high-value automated insulin delivery.

Midwest

The Midwest represented approximately USD 2.10 billion in 2025 and is expected to reach about USD 6.35 billion by 2035, equivalent to an estimated CAGR of approximately 11.7%.

The region includes Illinois, Indiana, Michigan, Ohio, Wisconsin, Iowa, Kansas, Minnesota, Missouri, Nebraska, North Dakota, and South Dakota.

The Midwest combines large health systems, major academic centers, substantial diabetes prevalence, strong employer-sponsored insurance in several metropolitan markets, and large rural populations. This creates simultaneous demand for advanced devices and value-oriented remote management.

Illinois is the largest state opportunity, led by Chicago’s extensive hospital, academic, and endocrinology ecosystem. Advanced CGM, insulin-pump, AID, and pediatric diabetes technologies have strong clinical infrastructure for adoption.

Ohio and Michigan represent substantial markets because of their population bases, chronic disease burden, major health systems, and large numbers of adults requiring longitudinal diabetes management. Cleveland, Columbus, Cincinnati, Detroit, and Ann Arbor provide important specialist and academic hubs.

Minnesota has outsized strategic relevance due to its medtech history, integrated health systems, and strong diabetes-technology expertise. It is an attractive market for clinical evaluation, sophisticated device use, and system-level procurement.

Wisconsin, Indiana, Missouri, Iowa, and Kansas provide stable demand through regional hospital networks, diabetes specialty programs, primary-care systems, and pharmacy distribution.

Nebraska, North Dakota, and South Dakota are smaller markets but highlight the value of connected care. Sparse populations and long travel distances increase the relevance of CGM sharing, remote therapy adjustment, telehealth-supported device initiation, and simplified technology.

The Midwest will remain a durable personalized diabetes device market through 2035. Companies that combine clinical training, payer support, reliable distribution, remote-service infrastructure, and strong relationships with integrated delivery networks should be best positioned.

Key Market Players

The U.S. Personalized Diabetes Care Devices competitive landscape is concentrated around a relatively small number of major CGM and insulin-delivery companies, but the wider ecosystem includes glucose-meter manufacturers, implantable-sensor developers, smart-injection companies, algorithm specialists, and connected chronic-care platforms.

Competition is increasingly ecosystem-based rather than device-based. CGM manufacturers are pursuing pump integrations, insulin-delivery companies are adding compatible sensor options, and traditional glucose-monitoring companies are adding connectivity and cloud-based management. This creates a competitive environment in which interoperability can be as strategically important as proprietary platform control.

Some of the key players operating in or influencing the U.S. personalized diabetes care device ecosystem include:

Abbott Diabetes Care
Dexcom, Inc.
Medtronic Diabetes
Insulet Corporation
Tandem Diabetes Care, Inc.
LifeScan, Inc.
Roche Diabetes Care
Ascensia Diabetes Care
Senseonics Holdings, Inc.
Beta Bionics, Inc.
Sequel Med Tech
embecta Corp.
Novo Nordisk
Eli Lilly and Company
CeQur Corporation
AgaMatrix, Inc.
Trividia Health, Inc.
i-SENS, Inc.
DarioHealth Corp.
Teladoc Health / Livongo
Glooko, Inc.

Abbott and Dexcom occupy particularly powerful positions because CGM is becoming the central data layer of personalized diabetes management. Their ability to expand sensor duration, improve access, develop OTC platforms, and establish integrations with insulin-delivery systems will influence the competitive architecture of the broader market.

Insulet, Tandem Diabetes Care, Medtronic, and Beta Bionics compete primarily through automated insulin delivery, but their strategic approaches differ in pump form factor, automation philosophy, sensor partnerships, patient setup, and workflow complexity. Type 2 diabetes expansion represents one of the most important competitive battlegrounds through the forecast period.

Senseonics provides differentiation through implantable long-duration CGM, while LifeScan, Roche, Ascensia, AgaMatrix, Trividia Health, and i-SENS participate in connected or conventional blood glucose monitoring. embecta, Novo Nordisk, Eli Lilly, and CeQur influence injection-based diabetes delivery and personalization.

The competitive advantage of device companies through 2035 will increasingly depend on five capabilities: recurring patient retention, broad reimbursement access, interoperability, demonstrable clinical outcomes, and low-friction patient experience. Accuracy remains essential, but accuracy alone is no longer sufficient to create sustainable market leadership.

Recent Developments

Recent developments in the U.S. Personalized Diabetes Care Devices Market demonstrate that the industry is moving rapidly beyond specialist-prescribed, insulin-centric diabetes technology.

In March 2024, the first over-the-counter continuous glucose monitor was cleared in the United States, creating a new access model for adults who do not use insulin. This was strategically significant because CGM historically depended heavily on prescription pathways and diabetes-specialist engagement. OTC availability expands the potential relationship between glucose sensing, lifestyle personalization, pharmacy access, and consumer-directed chronic disease management.

Abbott subsequently expanded the OTC glucose-sensing landscape through Libre Rio for adults with type 2 diabetes who do not use insulin and through its Lingo consumer biosensing strategy. These developments demonstrate that glucose-sensing technology is moving beyond intensive insulin management toward a broader continuum of metabolic decision support.

In August 2024, automated insulin-delivery technology reached a major market milestone when the indication for Insulet’s SmartAdjust technology was expanded to adults with type 2 diabetes. This represented the first U.S. authorization enabling automated insulin dosing for this population and materially widened the addressable AID market.

Long-duration CGM also advanced in September 2024 with U.S. clearance of the Eversense 365 system. A one-year implantable sensor introduces a fundamentally different value proposition from disposable sensors changed every 10 to 15 days. Its commercialization will test how much patients value reduced insertion frequency relative to the procedural requirement associated with implantable sensing.

The sensor-duration race continued in 2025 with regulatory clearance of Dexcom’s 15-day G7 configuration. Longer wear can reduce annual sensor-change frequency and may improve convenience and supply economics while strengthening the competitiveness of disposable CGM against alternative form factors.

Automated insulin delivery also continued to become more interoperable. Medtronic received U.S. approval for the Simplera Sync sensor with the MiniMed 780G system in 2025 and subsequently advanced integration of the 780G platform with an Abbott-manufactured sensor while expanding the system into insulin-requiring type 2 diabetes. These developments reinforce a broader market direction toward cross-company device compatibility rather than exclusively closed ecosystems.

In June 2026, the U.S. OTC CGM market expanded further when Stelo received clearance for non-insulin-using children aged two years and older. This development illustrates how quickly personalized glucose sensing is extending into populations outside its traditional adult intensive-insulin base.

The cumulative implication of these developments is significant. Personalized diabetes technology is no longer evolving through isolated improvements to sensors or pumps. Regulatory boundaries, patient populations, distribution channels, sensor duration, automation, and interoperability are all changing simultaneously. This creates both unusually strong market growth and higher competitive execution risk.

Conclusion

The U.S. Personalized Diabetes Care Devices Market Size & Share is positioned to expand from approximately USD 11.72 billion in 2025 to USD 36.40 billion by 2035, representing a CAGR of 12.00% during 2026–2035.

The underlying growth thesis is stronger than simple expansion of the U.S. diabetes population. The market is being structurally upgraded from episodic monitoring and manual treatment decisions toward continuous sensing, algorithm-enabled therapy, connected injection, remote clinical oversight, and individualized device ecosystems.

Continuous glucose monitoring will remain the largest product category, but automated insulin delivery is expected to generate some of the strongest incremental value creation. The extension of CGM and AID into type 2 diabetes is particularly important because it opens advanced technology to a substantially larger patient population than the historical type 1 market alone.

At the same time, personalization does not mean every patient will migrate to a premium pump or fully automated system. A large opportunity will remain for connected meters, smart injection technologies, simplified sensors, pharmacy-accessible devices, and hybrid remote-care models that provide an appropriate degree of personalization at lower cost and complexity.

Geographically, the South will remain the largest market because of population scale and diabetes burden. The West is expected to generate the fastest growth because of technology adoption, connected-care infrastructure, and consumer-oriented diabetes innovation. The Northeast will remain disproportionately influential in premium technology and clinical evidence generation, while the Midwest will provide a durable market anchored by major integrated health systems and substantial chronic disease demand.

For manufacturers, investors, healthcare systems, distributors, and strategic buyers, the central competitive question through 2035 will not be whether diabetes devices become more digital. That transition is already occurring. The more consequential question is which companies can convert continuous patient data into clinically reliable personalization while simultaneously reducing complexity for patients, clinicians, and payers.

Companies capable of combining accurate sensing, adaptive therapy, interoperable hardware, intuitive patient experience, recurring reimbursement, clinical evidence, and scalable remote-care integration will define the next decade of the U.S. personalized diabetes care devices industry.

TABLE OF CONTENT

1. U.S. Personalized Diabetes Care Devices Market: Market Introduction & Context

1.1. Market Definition
1.2. Scope of the Study
1.3. Research Methodology
1.3.1. Primary Data Collection
1.3.2. Secondary Data Sourcing
1.3.3. External Industry Collaborations
1.3.4. In-House Research Databases
1.3.5. Analytical Frameworks & Forecasting Models
1.3.6. Data Validation and Final Report Publishing
1.4. Key Assumptions
1.5. Market Ecosystem Overview
1.6. Stakeholder Analysis
1.6.1. Personalized Diabetes Device Manufacturers
1.6.2. Glucose Sensor, Semiconductor and Component Suppliers
1.6.3. Insulin Delivery and Connected Injection System Manufacturers
1.6.4. Endocrinology and Diabetes Specialty Practices
1.6.5. Hospitals and Integrated Health Systems
1.6.6. Pharmacy, DME and Diabetes Supply Distribution Channels
1.6.7. Medicare, Medicaid and Commercial Payers
1.6.8. Patients, Caregivers and Diabetes Educators
1.6.9. FDA, CMS and Other Clinical Decision-Makers

What this section provides: This section establishes the precise market boundary, device inclusion criteria, study methodology, assumptions, and stakeholder ecosystem used to measure and forecast the U.S. Personalized Diabetes Care Devices Market.

2. U.S. Personalized Diabetes Care Devices Market: Executive Summary

2.1. Key Insights & Market Snapshot
2.2. Analyst Viewpoint
2.3. Market Attractiveness Index
2.4. Historical Market Summary, 2021–2024
2.5. Base Year Market Positioning, 2025
2.6. Forecast Outlook, 2026–2035
2.7. U.S. Personalized Diabetes Device Adoption Indicators
2.8. High-Growth Opportunity Areas
2.8.1. Continuous Glucose Monitoring Expansion
2.8.2. Automated Insulin Delivery Penetration
2.8.3. Type 2 Diabetes Technology Adoption
2.8.4. OTC and Consumer-Accessible Glucose Sensing
2.8.5. Smart Insulin Injection and Dose-Tracking Systems
2.8.6. Long-Duration and Implantable Glucose Monitoring
2.8.7. AI-Assisted and Predictive Diabetes Management

What this section provides: This section gives decision-makers an executive view of market size, historical expansion, forecast growth, technology adoption, competitive direction, and the highest-value personalized diabetes device opportunities through 2035.

3. U.S. Personalized Diabetes Care Devices Market: Market Dynamics & Outlook

3.1. Drivers and Their Impact Analysis
3.1.1. Rising U.S. Diabetes and Prediabetes Burden
3.1.2. Accelerating Continuous Glucose Monitoring Adoption
3.1.3. Broader Medicare and Commercial Payer CGM Coverage
3.1.4. Automated Insulin Delivery Expansion into Type 2 Diabetes
3.1.5. Growing Demand for Individualized Glucose Management
3.1.6. Shift from Episodic Testing to Continuous Patient Monitoring
3.1.7. Expansion of Remote and Virtual Diabetes Management
3.1.8. Increasing Patient Preference for Lower-Burden Diabetes Technology
3.2. Restraints and Their Impact Analysis
3.2.1. High Device and Recurring Consumable Costs
3.2.2. Variability in Insurance Coverage and Patient Out-of-Pocket Expense
3.2.3. Device Wearability, Alarm Fatigue and Treatment Burden
3.2.4. Interoperability and Diabetes Data Fragmentation
3.2.5. Training Requirements and Specialist Workforce Constraints
3.2.6. Cybersecurity, Privacy and Connected-Device Risks
3.3. Opportunities and Their Impact Analysis
3.3.1. OTC Continuous Glucose Monitoring Expansion
3.3.2. Type 2 Diabetes Automated Insulin Delivery
3.3.3. Long-Duration and Implantable Glucose Sensors
3.3.4. Connected Insulin Pens and Smart Injection Systems
3.3.5. AI-Powered Glucose Prediction and Decision Support
3.3.6. Personalized Diabetes Management in Primary Care
3.3.7. Remote Monitoring for Rural and Underserved Populations
3.3.8. Pediatric and Pregnancy-Associated Diabetes Technology
3.4. Challenges and Their Impact Analysis
3.5. Patent & Innovation Analysis, 2021–2025
3.6. Personalized Diabetes Device Clinical Workflow Economics Analysis
3.7. Patient Lifetime Device Economics and Recurring Consumable Analysis
3.8. Payer and Health System Technology Evaluation Behavior Analysis

What this section provides: This section examines the clinical, economic, technological, reimbursement, patient-behavior, and operational forces shaping personalized diabetes device adoption and identifies the principal commercial opportunities and execution risks through 2035.

4. U.S. Personalized Diabetes Care Devices Market: Market Environment & Industry Analysis

4.1. PESTEL Analysis
4.1.1. Political
4.1.2. Economic
4.1.3. Social
4.1.4. Technological
4.1.5. Environmental
4.1.6. Legal
4.2. Porter’s Five Forces Analysis
4.2.1. Threat of New Entrants
4.2.2. Bargaining Power of Buyers
4.2.3. Bargaining Power of Suppliers
4.2.4. Substitution Risk
4.2.5. Competitive Rivalry
4.3. Pricing Trend Analysis by Region, 2025–2035
4.4. Value Chain & Supply Chain Analysis
4.5. Impact of Digitalization, Connectivity and Diabetes Device Interoperability
4.6. Application & Innovation Landscape
4.7. FDA Regulatory Framework Analysis
4.7.1. Continuous Glucose Monitoring Regulatory Pathways
4.7.2. Automated Insulin Delivery Regulatory Requirements
4.7.3. Interoperable CGM and Insulin Pump Framework
4.7.4. Connected Diabetes Device Software and Algorithm Regulation
4.7.5. OTC Diabetes Device Regulatory Landscape
4.8. CMS Reimbursement and Coverage Landscape
4.8.1. Medicare CGM Coverage
4.8.2. Insulin Pump and AID Coverage
4.8.3. DME Versus Pharmacy Benefit Dynamics
4.8.4. Medicaid Coverage Variability
4.8.5. Commercial Payer Coverage Trends
4.9. Cybersecurity, HIPAA and Patient Data Governance
4.10. Import/Export Restrictions, Tariffs and Supply Chain Exposure
4.11. Government Diabetes Prevention and Chronic Care Initiatives
4.12. Impact of Escalating Geopolitical and Semiconductor Supply Risks
4.13. Payer and Health System Diabetes Technology Evaluation Framework

What this section provides: This section provides a comprehensive assessment of regulation, reimbursement, pricing, digital integration, supply chain, cybersecurity, competition, and payer decision-making affecting the U.S. Personalized Diabetes Care Devices Market.

5. U.S. Personalized Diabetes Care Devices Market – By Product Category

5.1. Overview
5.1.1. Segment Share Analysis, By Product Category, 2025 & 2035 (%)
5.1.2. Continuous Glucose Monitoring and Personalized Biosensor Systems
5.1.2.1. Real-Time CGM Systems
5.1.2.2. Intermittently Scanned CGM Systems
5.1.2.3. Disposable CGM Sensors
5.1.2.4. Implantable CGM Sensors
5.1.2.5. OTC and Consumer-Accessible CGM Systems
5.1.2.6. CGM Transmitters, Receivers and Accessories
5.1.3. Automated Insulin Delivery Systems and Connected Insulin Pumps
5.1.3.1. Tubed Insulin Pumps
5.1.3.2. Tubeless and Patch Pump Systems
5.1.3.3. Hybrid Closed-Loop Systems
5.1.3.4. Automated Insulin Delivery Controllers
5.1.3.5. Infusion Sets, Pods and Related Consumables
5.1.4. Smart Insulin Pens and Connected Injection Systems
5.1.4.1. Reusable Smart Insulin Pens
5.1.4.2. Connected Disposable Insulin Pens
5.1.4.3. Smart Pen Caps and Dose-Tracking Accessories
5.1.4.4. Patch-Based Insulin Injection Systems
5.1.4.5. Connected Dose Calculation and Insulin Tracking Systems
5.1.5. Connected Blood Glucose Monitoring Systems
5.1.5.1. Bluetooth-Enabled Blood Glucose Meters
5.1.5.2. Cellular-Connected Blood Glucose Meters
5.1.5.3. Connected Test Strip Ecosystems
5.1.5.4. Cloud-Integrated Glucose Monitoring Systems
5.1.6. Implantable and Adjunct Personalized Diabetes Devices
5.1.6.1. Long-Duration Implantable Glucose Monitoring Devices
5.1.6.2. Personalized Diabetes Connectivity Accessories
5.1.6.3. Multi-Parameter Metabolic Monitoring Devices
5.1.6.4. Emerging Personalized Diabetes Wearables

What this section provides: This section identifies which personalized diabetes device categories are expected to generate the largest revenue pools, strongest recurring consumable economics, and fastest growth through 2035.

6. U.S. Personalized Diabetes Care Devices Market – By Application

6.1. Overview
6.1.1. Segment Share Analysis, By Application, 2025 & 2035 (%)
6.1.2. Type 1 Diabetes Management
6.1.2.1. Adult Type 1 Diabetes
6.1.2.2. Pediatric and Adolescent Type 1 Diabetes
6.1.2.3. Intensive Insulin Therapy Management
6.1.2.4. Hypoglycemia Prevention and Time-in-Range Optimization
6.1.3. Insulin-Requiring Type 2 Diabetes
6.1.3.1. Basal Insulin Users
6.1.3.2. Multiple Daily Injection Users
6.1.3.3. Pump-Based Type 2 Diabetes Management
6.1.3.4. Automated Insulin Delivery for Type 2 Diabetes
6.1.4. Non-Insulin-Treated Type 2 Diabetes
6.1.4.1. CGM-Guided Lifestyle Management
6.1.4.2. Medication Response Monitoring
6.1.4.3. Behavioral and Nutritional Personalization
6.1.4.4. OTC Glucose Monitoring Applications
6.1.5. Gestational and Pregnancy-Associated Diabetes Management
6.1.5.1. Gestational Diabetes Monitoring
6.1.5.2. Pre-Existing Type 1 Diabetes in Pregnancy
6.1.5.3. Pre-Existing Type 2 Diabetes in Pregnancy
6.1.6. Secondary, Complex and High-Risk Diabetes Management
6.1.6.1. Severe Hypoglycemia Risk Management
6.1.6.2. Steroid-Induced and Secondary Diabetes
6.1.6.3. Diabetes with Chronic Kidney Disease
6.1.6.4. Highly Variable and Complex Glycemic Management

What this section provides: This section helps clients quantify device demand by diabetes population and identify applications where personalized sensing, insulin automation, connected dosing, and continuous monitoring generate the greatest clinical and commercial value.

7. U.S. Personalized Diabetes Care Devices Market – By End User

7.1. Overview
7.1.1. Segment Share Analysis, By End User, 2025 & 2035 (%)
7.1.2. Patients and Home Users
7.1.2.1. Adult Diabetes Patients
7.1.2.2. Pediatric and Adolescent Users
7.1.2.3. Older Adults and Medicare Beneficiaries
7.1.2.4. Caregiver-Supported Users
7.1.3. Endocrinology and Diabetes Specialty Clinics
7.1.3.1. Independent Endocrinology Practices
7.1.3.2. Hospital-Affiliated Diabetes Centers
7.1.3.3. Pediatric Endocrinology Centers
7.1.3.4. Diabetes Education and Technology Clinics
7.1.4. Hospitals and Integrated Health Systems
7.1.4.1. Academic Medical Centers
7.1.4.2. Integrated Delivery Networks
7.1.4.3. Community Hospitals
7.1.4.4. Population Health Programs
7.1.5. Primary Care and Multispecialty Practices
7.1.5.1. Primary Care Practices
7.1.5.2. Internal Medicine Practices
7.1.5.3. Multispecialty Physician Groups
7.1.5.4. Federally Qualified and Community Health Centers
7.1.6. Remote Diabetes Management and Home Healthcare Providers
7.1.6.1. Virtual Diabetes Management Providers
7.1.6.2. Home Healthcare Organizations
7.1.6.3. Payer-Sponsored Diabetes Management Programs
7.1.6.4. Employer-Sponsored Diabetes Management Programs

What this section provides: This section explains which patient groups and care-delivery settings are driving personalized diabetes device initiation, utilization, recurring sensor demand, insulin delivery adoption, and remote monitoring growth.

8. U.S. Personalized Diabetes Care Devices Market – By Technology Type

8.1. Overview
8.1.1. Segment Share Analysis, By Technology Type, 2025 & 2035 (%)
8.1.2. Real-Time Continuous Glucose Monitoring Technology
8.1.2.1. Subcutaneous Electrochemical Sensing
8.1.2.2. Predictive Alert Technology
8.1.2.3. Smartphone-Connected CGM
8.1.2.4. Caregiver and Remote Data Sharing
8.1.3. Intermittently Scanned and Consumer-Accessible Glucose Sensing
8.1.3.1. Flash Glucose Monitoring
8.1.3.2. OTC Glucose Sensor Technology
8.1.3.3. Consumer-Accessible Metabolic Biosensing
8.1.4. Automated and Adaptive Insulin-Control Technology
8.1.4.1. Hybrid Closed-Loop Algorithms
8.1.4.2. Adaptive Basal Insulin Delivery
8.1.4.3. Automated Correction Technology
8.1.4.4. Alternate Controller Enabled Insulin Delivery
8.1.4.5. Personalized Glucose Target Algorithms
8.1.5. Connected Injection and Dose-Tracking Technology
8.1.5.1. Bluetooth-Enabled Insulin Pens
8.1.5.2. Smart Dose Memory Technology
8.1.5.3. Insulin-on-Board Calculation Technology
8.1.5.4. Injection Adherence Monitoring
8.1.6. AI-Enabled, Predictive and Interoperable Device Ecosystems
8.1.6.1. AI-Based Glucose Pattern Recognition
8.1.6.2. Hypoglycemia and Hyperglycemia Prediction
8.1.6.3. Connected Diabetes Device Interoperability
8.1.6.4. Remote Clinical Decision-Support Technology
8.1.6.5. Personalized Patient Risk Stratification

What this section provides: This section evaluates the sensing, automation, connectivity, predictive intelligence, and interoperability technologies that are transforming personalized diabetes management in the United States.

9. U.S. Personalized Diabetes Care Devices Market – By Geography

9.1. Introduction
9.1.1. Segment Share Analysis, By Geography, 2025 & 2035 (%)
9.1.2. Regional Market Size and Forecast, 2021–2035 (US$ Billion)
9.1.3. Regional Diabetes Burden and Eligible Patient Population Analysis
9.1.4. Regional CGM, Insulin Pump and AID Penetration Analysis
9.1.5. Regional Reimbursement, Payer Coverage and Device Access Dynamics
9.2. West Region
9.2.1. Regional Overview & Trends
9.2.2. West Region Personalized Diabetes Device Key Manufacturers and Market Access Ecosystem
9.2.3. West Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
9.2.4. West Region Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.2.5. West Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.2.6. West Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.2.7. West Region Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
9.2.8. West Region Reimbursement, Distribution and Personalized Device Adoption Dynamics
9.2.9. California
9.2.9.1. Overview
9.2.9.2. California Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.2.9.3. California Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.2.9.4. California Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.2.9.5. California Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
9.2.9.6. California Reimbursement, Device Access and Adoption Dynamics
9.2.10. Washington
9.2.10.1. Overview
9.2.10.2. Washington Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.2.10.3. Washington Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.2.10.4. Washington Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.2.10.5. Washington Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
9.2.10.6. Washington Reimbursement, Device Access and Adoption Dynamics
9.2.11. Arizona
9.2.11.1. Overview
9.2.11.2. Arizona Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.2.11.3. Arizona Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.2.11.4. Arizona Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.2.11.5. Arizona Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
9.2.11.6. Arizona Reimbursement, Device Access and Adoption Dynamics
9.2.12. Colorado
9.2.12.1. Overview
9.2.12.2. Colorado Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.2.12.3. Colorado Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.2.12.4. Colorado Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.2.12.5. Colorado Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
9.2.12.6. Colorado Reimbursement, Device Access and Adoption Dynamics
9.2.13. Oregon
9.2.13.1. Overview
9.2.13.2. Oregon Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.2.13.3. Oregon Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.2.13.4. Oregon Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.2.13.5. Oregon Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
9.2.13.6. Oregon Reimbursement, Device Access and Adoption Dynamics
9.2.14. Utah
9.2.14.1. Overview
9.2.14.2. Utah Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.2.14.3. Utah Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.2.14.4. Utah Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.2.14.5. Utah Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
9.2.14.6. Utah Reimbursement, Device Access and Adoption Dynamics
9.2.15. Nevada
9.2.15.1. Overview
9.2.15.2. Nevada Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.2.15.3. Nevada Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.2.15.4. Nevada Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.2.15.5. Nevada Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
9.2.15.6. Nevada Reimbursement, Device Access and Adoption Dynamics
9.2.16. New Mexico
9.2.16.1. Overview
9.2.16.2. New Mexico Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.2.16.3. New Mexico Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.2.16.4. New Mexico Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.2.16.5. New Mexico Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
9.2.16.6. New Mexico Reimbursement, Device Access and Adoption Dynamics
9.2.17. Idaho
9.2.17.1. Overview
9.2.17.2. Idaho Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.2.17.3. Idaho Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.2.17.4. Idaho Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.2.17.5. Idaho Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
9.2.17.6. Idaho Reimbursement, Device Access and Adoption Dynamics
9.2.18. Montana
9.2.18.1. Overview
9.2.18.2. Montana Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.2.18.3. Montana Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.2.18.4. Montana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.2.18.5. Montana Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
9.2.18.6. Montana Reimbursement, Device Access and Adoption Dynamics
9.2.19. Wyoming
9.2.19.1. Overview
9.2.19.2. Wyoming Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.2.19.3. Wyoming Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.2.19.4. Wyoming Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.2.19.5. Wyoming Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
9.2.19.6. Wyoming Reimbursement, Device Access and Adoption Dynamics
9.2.20. Alaska
9.2.20.1. Overview
9.2.20.2. Alaska Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.2.20.3. Alaska Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.2.20.4. Alaska Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.2.20.5. Alaska Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
9.2.20.6. Alaska Reimbursement, Device Access and Adoption Dynamics
9.2.21. Hawaii
9.2.21.1. Overview
9.2.21.2. Hawaii Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.2.21.3. Hawaii Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.2.21.4. Hawaii Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.2.21.5. Hawaii Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
9.2.21.6. Hawaii Reimbursement, Device Access and Adoption Dynamics
9.3. Northeast Region
9.3.1. Regional Overview & Trends
9.3.2. Northeast Region Personalized Diabetes Device Key Manufacturers and Market Access Ecosystem
9.3.3. Northeast Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
9.3.4. Northeast Region Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.3.5. Northeast Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.3.6. Northeast Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.3.7. Northeast Region Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
9.3.8. Northeast Region Reimbursement, Distribution and Personalized Device Adoption Dynamics
9.3.9. New York
9.3.9.1. Overview
9.3.9.2. New York Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.3.9.3. New York Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.3.9.4. New York Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.3.9.5. New York Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
9.3.9.6. New York Reimbursement, Device Access and Adoption Dynamics
9.3.10. Massachusetts
9.3.10.1. Overview
9.3.10.2. Massachusetts Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.3.10.3. Massachusetts Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.3.10.4. Massachusetts Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.3.10.5. Massachusetts Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
9.3.10.6. Massachusetts Reimbursement, Device Access and Adoption Dynamics
9.3.11. New Jersey
9.3.11.1. Overview
9.3.11.2. New Jersey Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.3.11.3. New Jersey Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.3.11.4. New Jersey Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.3.11.5. New Jersey Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
9.3.11.6. New Jersey Reimbursement, Device Access and Adoption Dynamics
9.3.12. Pennsylvania
9.3.12.1. Overview
9.3.12.2. Pennsylvania Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.3.12.3. Pennsylvania Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.3.12.4. Pennsylvania Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.3.12.5. Pennsylvania Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
9.3.12.6. Pennsylvania Reimbursement, Device Access and Adoption Dynamics
9.3.13. Connecticut
9.3.13.1. Overview
9.3.13.2. Connecticut Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.3.13.3. Connecticut Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.3.13.4. Connecticut Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.3.13.5. Connecticut Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
9.3.13.6. Connecticut Reimbursement, Device Access and Adoption Dynamics
9.3.14. Maine
9.3.14.1. Overview
9.3.14.2. Maine Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.3.14.3. Maine Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.3.14.4. Maine Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.3.14.5. Maine Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
9.3.14.6. Maine Reimbursement, Device Access and Adoption Dynamics
9.3.15. Vermont
9.3.15.1. Overview
9.3.15.2. Vermont Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.3.15.3. Vermont Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.3.15.4. Vermont Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.3.15.5. Vermont Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
9.3.15.6. Vermont Reimbursement, Device Access and Adoption Dynamics
9.3.16. New Hampshire
9.3.16.1. Overview
9.3.16.2. New Hampshire Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.3.16.3. New Hampshire Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.3.16.4. New Hampshire Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.3.16.5. New Hampshire Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
9.3.16.6. New Hampshire Reimbursement, Device Access and Adoption Dynamics
9.3.17. Rhode Island
9.3.17.1. Overview
9.3.17.2. Rhode Island Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.3.17.3. Rhode Island Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.3.17.4. Rhode Island Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.3.17.5. Rhode Island Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
9.3.17.6. Rhode Island Reimbursement, Device Access and Adoption Dynamics
9.3.18. Delaware
9.3.18.1. Overview
9.3.18.2. Delaware Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.3.18.3. Delaware Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.3.18.4. Delaware Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.3.18.5. Delaware Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
9.3.18.6. Delaware Reimbursement, Device Access and Adoption Dynamics
9.4. South Region
9.4.1. Regional Overview & Trends
9.4.2. South Region Personalized Diabetes Device Key Manufacturers and Market Access Ecosystem
9.4.3. South Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
9.4.4. South Region Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.4.5. South Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.4.6. South Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.4.7. South Region Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
9.4.8. South Region Reimbursement, Distribution and Personalized Device Adoption Dynamics
9.4.9. Texas
9.4.9.1. Overview
9.4.9.2. Texas Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.4.9.3. Texas Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.4.9.4. Texas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.4.9.5. Texas Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
9.4.9.6. Texas Reimbursement, Device Access and Adoption Dynamics
9.4.10. Florida
9.4.10.1. Overview
9.4.10.2. Florida Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.4.10.3. Florida Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.4.10.4. Florida Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.4.10.5. Florida Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
9.4.10.6. Florida Reimbursement, Device Access and Adoption Dynamics
9.4.11. Georgia
9.4.11.1. Overview
9.4.11.2. Georgia Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.4.11.3. Georgia Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.4.11.4. Georgia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.4.11.5. Georgia Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
9.4.11.6. Georgia Reimbursement, Device Access and Adoption Dynamics
9.4.12. North Carolina
9.4.12.1. Overview
9.4.12.2. North Carolina Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.4.12.3. North Carolina Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.4.12.4. North Carolina Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.4.12.5. North Carolina Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
9.4.12.6. North Carolina Reimbursement, Device Access and Adoption Dynamics
9.4.13. Tennessee
9.4.13.1. Overview
9.4.13.2. Tennessee Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.4.13.3. Tennessee Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.4.13.4. Tennessee Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.4.13.5. Tennessee Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
9.4.13.6. Tennessee Reimbursement, Device Access and Adoption Dynamics
9.4.14. South Carolina
9.4.14.1. Overview
9.4.14.2. South Carolina Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.4.14.3. South Carolina Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.4.14.4. South Carolina Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.4.14.5. South Carolina Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
9.4.14.6. South Carolina Reimbursement, Device Access and Adoption Dynamics
9.4.15. Alabama
9.4.15.1. Overview
9.4.15.2. Alabama Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.4.15.3. Alabama Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.4.15.4. Alabama Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.4.15.5. Alabama Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
9.4.15.6. Alabama Reimbursement, Device Access and Adoption Dynamics
9.4.16. Mississippi
9.4.16.1. Overview
9.4.16.2. Mississippi Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.4.16.3. Mississippi Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.4.16.4. Mississippi Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.4.16.5. Mississippi Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
9.4.16.6. Mississippi Reimbursement, Device Access and Adoption Dynamics
9.4.17. Louisiana
9.4.17.1. Overview
9.4.17.2. Louisiana Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.4.17.3. Louisiana Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.4.17.4. Louisiana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.4.17.5. Louisiana Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
9.4.17.6. Louisiana Reimbursement, Device Access and Adoption Dynamics
9.4.18. Arkansas
9.4.18.1. Overview
9.4.18.2. Arkansas Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.4.18.3. Arkansas Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.4.18.4. Arkansas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.4.18.5. Arkansas Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
9.4.18.6. Arkansas Reimbursement, Device Access and Adoption Dynamics
9.4.19. Kentucky
9.4.19.1. Overview
9.4.19.2. Kentucky Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.4.19.3. Kentucky Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.4.19.4. Kentucky Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.4.19.5. Kentucky Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
9.4.19.6. Kentucky Reimbursement, Device Access and Adoption Dynamics
9.4.20. Oklahoma
9.4.20.1. Overview
9.4.20.2. Oklahoma Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.4.20.3. Oklahoma Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.4.20.4. Oklahoma Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.4.20.5. Oklahoma Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
9.4.20.6. Oklahoma Reimbursement, Device Access and Adoption Dynamics
9.4.21. Virginia
9.4.21.1. Overview
9.4.21.2. Virginia Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.4.21.3. Virginia Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.4.21.4. Virginia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.4.21.5. Virginia Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
9.4.21.6. Virginia Reimbursement, Device Access and Adoption Dynamics
9.4.22. Maryland
9.4.22.1. Overview
9.4.22.2. Maryland Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.4.22.3. Maryland Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.4.22.4. Maryland Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.4.22.5. Maryland Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
9.4.22.6. Maryland Reimbursement, Device Access and Adoption Dynamics
9.4.23. West Virginia
9.4.23.1. Overview
9.4.23.2. West Virginia Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.4.23.3. West Virginia Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.4.23.4. West Virginia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.4.23.5. West Virginia Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
9.4.23.6. West Virginia Reimbursement, Device Access and Adoption Dynamics
9.5. Midwest Region
9.5.1. Regional Overview & Trends
9.5.2. Midwest Region Personalized Diabetes Device Key Manufacturers and Market Access Ecosystem
9.5.3. Midwest Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
9.5.4. Midwest Region Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.5.5. Midwest Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.5.6. Midwest Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.5.7. Midwest Region Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
9.5.8. Midwest Region Reimbursement, Distribution and Personalized Device Adoption Dynamics
9.5.9. Illinois
9.5.9.1. Overview
9.5.9.2. Illinois Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.5.9.3. Illinois Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.5.9.4. Illinois Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.5.9.5. Illinois Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
9.5.9.6. Illinois Reimbursement, Device Access and Adoption Dynamics
9.5.10. Ohio
9.5.10.1. Overview
9.5.10.2. Ohio Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.5.10.3. Ohio Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.5.10.4. Ohio Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.5.10.5. Ohio Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
9.5.10.6. Ohio Reimbursement, Device Access and Adoption Dynamics
9.5.11. Michigan
9.5.11.1. Overview
9.5.11.2. Michigan Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.5.11.3. Michigan Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.5.11.4. Michigan Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.5.11.5. Michigan Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
9.5.11.6. Michigan Reimbursement, Device Access and Adoption Dynamics
9.5.12. Minnesota
9.5.12.1. Overview
9.5.12.2. Minnesota Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.5.12.3. Minnesota Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.5.12.4. Minnesota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.5.12.5. Minnesota Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
9.5.12.6. Minnesota Reimbursement, Device Access and Adoption Dynamics
9.5.13. Indiana
9.5.13.1. Overview
9.5.13.2. Indiana Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.5.13.3. Indiana Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.5.13.4. Indiana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.5.13.5. Indiana Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
9.5.13.6. Indiana Reimbursement, Device Access and Adoption Dynamics
9.5.14. Wisconsin
9.5.14.1. Overview
9.5.14.2. Wisconsin Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.5.14.3. Wisconsin Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.5.14.4. Wisconsin Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.5.14.5. Wisconsin Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
9.5.14.6. Wisconsin Reimbursement, Device Access and Adoption Dynamics
9.5.15. Missouri
9.5.15.1. Overview
9.5.15.2. Missouri Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.5.15.3. Missouri Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.5.15.4. Missouri Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.5.15.5. Missouri Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
9.5.15.6. Missouri Reimbursement, Device Access and Adoption Dynamics
9.5.16. Iowa
9.5.16.1. Overview
9.5.16.2. Iowa Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.5.16.3. Iowa Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.5.16.4. Iowa Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.5.16.5. Iowa Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
9.5.16.6. Iowa Reimbursement, Device Access and Adoption Dynamics
9.5.17. Kansas
9.5.17.1. Overview
9.5.17.2. Kansas Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.5.17.3. Kansas Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.5.17.4. Kansas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.5.17.5. Kansas Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
9.5.17.6. Kansas Reimbursement, Device Access and Adoption Dynamics
9.5.18. Nebraska
9.5.18.1. Overview
9.5.18.2. Nebraska Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.5.18.3. Nebraska Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.5.18.4. Nebraska Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.5.18.5. Nebraska Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
9.5.18.6. Nebraska Reimbursement, Device Access and Adoption Dynamics
9.5.19. North Dakota
9.5.19.1. Overview
9.5.19.2. North Dakota Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.5.19.3. North Dakota Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.5.19.4. North Dakota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.5.19.5. North Dakota Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
9.5.19.6. North Dakota Reimbursement, Device Access and Adoption Dynamics
9.5.20. South Dakota
9.5.20.1. Overview
9.5.20.2. South Dakota Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.5.20.3. South Dakota Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.5.20.4. South Dakota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.5.20.5. South Dakota Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
9.5.20.6. South Dakota Reimbursement, Device Access and Adoption Dynamics

What this section provides: This section delivers comprehensive regional and state-level intelligence across all 50 U.S. states, enabling clients to identify personalized diabetes device adoption hotspots, high-burden diabetes markets, CGM and AID opportunities, payer-access differences, and state-level commercial priorities.

10. U.S. Personalized Diabetes Care Devices Market: Competitive Landscape & Company Profiles

10.1. Market Share Analysis, 2025
10.2. Company Positioning Matrix
10.2.1. Leaders
10.2.2. Challengers
10.2.3. Innovators
10.2.4. Emerging Players
10.3. Competitive Benchmarking
10.3.1. CGM Portfolio Strength
10.3.2. Automated Insulin Delivery Capabilities
10.3.3. Smart Injection and Connected Dosing Capabilities
10.3.4. Device Interoperability
10.3.5. Medicare and Commercial Payer Access
10.3.6. Patient Installed Base and Recurring Consumable Model
10.3.7. U.S. Regulatory and Clinical Pipeline
10.4. Company Profiles
10.4.1. Abbott Diabetes Care
10.4.2. Dexcom, Inc.
10.4.3. Medtronic Diabetes
10.4.4. Insulet Corporation
10.4.5. Tandem Diabetes Care, Inc.
10.4.6. LifeScan, Inc.
10.4.7. Roche Diabetes Care
10.4.8. Ascensia Diabetes Care
10.4.9. Senseonics Holdings, Inc.
10.4.10. Beta Bionics, Inc.
10.4.11. Sequel Med Tech
10.4.12. embecta Corp.
10.4.13. Novo Nordisk
10.4.14. Eli Lilly and Company
10.4.15. CeQur Corporation
10.4.16. AgaMatrix, Inc.
10.4.17. Trividia Health, Inc.
10.4.18. i-SENS, Inc.
10.4.19. DarioHealth Corp.
10.4.20. Glooko, Inc.
10.4.21. Teladoc Health / Livongo
10.4.22. Smart Meter LLC
10.4.23. FORA Care
10.4.24. Prodigy Diabetes Care
10.4.25. Modular Medical, Inc.

Note: Each company profile will include company overview, personalized diabetes device portfolio, U.S. market strategy, product positioning, regulatory status, reimbursement access, interoperability strategy, clinical evidence, partnerships, financial positioning, pipeline activity, and recent developments.

What this section provides: This section gives clients competitive benchmarking, market-share visibility, portfolio positioning, technology differentiation, reimbursement strategy, interoperability intelligence, and strategic assessment of leading and emerging personalized diabetes device companies.

11. U.S. Personalized Diabetes Care Devices Market: Future Market Outlook, 2026–2035

11.1. Scenario Analysis
11.1.1. Optimistic Scenario
11.1.2. Realistic Scenario
11.1.3. Pessimistic Scenario
11.2. Disruptive Technologies Impact
11.2.1. Next-Generation Long-Wear CGM
11.2.2. Fully and Highly Automated Insulin Delivery
11.2.3. OTC and Consumer-Accessible Glucose Biosensing
11.2.4. Smart Insulin Injection and Dose Automation
11.2.5. Implantable Continuous Glucose Monitoring
11.2.6. AI-Assisted Predictive Glucose Management
11.2.7. Multi-Hormone and Next-Generation Automated Delivery
11.2.8. Remote Diabetes Management and Virtual Care Integration
11.3. Emerging Business Trends
11.4. Transition from Standalone Devices to Personalized Diabetes Ecosystems
11.5. Expansion of Advanced Diabetes Devices into Type 2 Diabetes
11.6. Pharmacy Channel and OTC Distribution Evolution
11.7. Business Opportunities for Startups and Existing Players
11.8. Investment Prioritization Matrix
11.9. Technology Adoption Roadmap, 2026–2035

What this section provides: This section prepares clients for future changes in sensing, automation, personalized therapy, interoperability, distribution, payer access, and market structure and identifies the technologies and business models most likely to influence growth through 2035.

12. U.S. Personalized Diabetes Care Devices Market: Strategic Recommendations

12.1. Recommendations for Diabetes Device Manufacturers
12.2. Recommendations for Hospitals, Endocrinology Networks and Integrated Health Systems
12.3. Recommendations for Medicare Advantage, Medicaid and Commercial Payers
12.4. Recommendations for Investors and Private Equity Firms
12.5. Recommendations for Pharmacies, DME Suppliers and Distribution Partners
12.6. Recommendations for Virtual Diabetes Management Providers
12.7. Recommendations for New Entrants and Startups
12.8. Go-to-Market Strategy Considerations
12.8.1. Patient Acquisition Strategy
12.8.2. Endocrinologist and Primary Care Engagement
12.8.3. Medicare and Commercial Payer Market Access
12.8.4. Pharmacy Versus DME Channel Strategy
12.8.5. Patient Training and Retention Strategy
12.8.6. Interoperability Partnership Strategy
12.9. Product Positioning and Portfolio Expansion Guidance
12.10. High-Priority U.S. State Market Entry Strategy

What this section provides: This section translates market intelligence into actionable recommendations for product development, reimbursement strategy, channel expansion, patient acquisition, geographic prioritization, investment planning, and competitive differentiation.

13. U.S. Personalized Diabetes Care Devices Market: Disclaimer

13.1. Scope Limitation
13.2. Data Use Limitation
13.3. Forecasting Limitation
13.4. Legal Disclaimer
13.5. Third-Party Data Disclaimer
13.6. Market Modeling and Estimate Disclaimer

What this section provides: This section defines the report’s scope limitations, data-use boundaries, forecast assumptions, market-modeling constraints, legal considerations, and treatment of third-party information.

List of Tables

TABLE 1: List of Data Sources
TABLE 2: U.S. Personalized Diabetes Care Devices Market: Market Definition and Scope
TABLE 3: U.S. Personalized Diabetes Care Devices Market: Research Methodology Framework
TABLE 4: U.S. Personalized Diabetes Care Devices Market: Key Assumptions
TABLE 5: U.S. Personalized Diabetes Care Devices Market: Market Ecosystem Overview
TABLE 6: U.S. Personalized Diabetes Care Devices Market: Stakeholder Analysis
TABLE 7: U.S. Personalized Diabetes Care Devices Market: Executive Summary Snapshot, 2025
TABLE 8: U.S. Personalized Diabetes Care Devices Market: Analyst Viewpoint Summary
TABLE 9: U.S. Personalized Diabetes Care Devices Market: Market Attractiveness Index
TABLE 10: U.S. Personalized Diabetes Care Devices Market: Historical Market Size, 2021–2024 (US$ Billion)
TABLE 11: U.S. Personalized Diabetes Care Devices Market: Base Year Market Positioning, 2025
TABLE 12: U.S. Personalized Diabetes Care Devices Market: Forecast Market Size, 2026–2035 (US$ Billion)
TABLE 13: U.S. Personalized Diabetes Care Devices Market: Year-wise Market Size, 2021–2035 (US$ Billion)
TABLE 14: U.S. Personalized Diabetes Care Devices Market: High-Growth Opportunity Areas
TABLE 15: U.S. Personalized Diabetes Care Devices Market: Drivers; Impact Analysis
TABLE 16: U.S. Personalized Diabetes Care Devices Market: Restraints; Impact Analysis
TABLE 17: U.S. Personalized Diabetes Care Devices Market: Opportunities; Impact Analysis
TABLE 18: U.S. Personalized Diabetes Care Devices Market: Challenges; Impact Analysis
TABLE 19: U.S. Personalized Diabetes Care Devices Market: Patent & Innovation Analysis, 2021–2025
TABLE 20: U.S. Personalized Diabetes Care Devices Market: Clinical Workflow Economics Matrix
TABLE 21: U.S. Personalized Diabetes Care Devices Market: Patient Lifetime Device Economics and Recurring Consumable Matrix
TABLE 22: U.S. Personalized Diabetes Care Devices Market: Payer and Health System Technology Evaluation Matrix
TABLE 23: U.S. Personalized Diabetes Care Devices Market: PESTEL Analysis
TABLE 24: U.S. Personalized Diabetes Care Devices Market: Porter’s Five Forces Analysis
TABLE 25: U.S. Personalized Diabetes Care Devices Market: Pricing Trend Analysis by Region, 2025–2035
TABLE 26: U.S. Personalized Diabetes Care Devices Market: Value Chain Analysis
TABLE 27: U.S. Personalized Diabetes Care Devices Market: Supply Chain Analysis
TABLE 28: U.S. Personalized Diabetes Care Devices Market: Digitalization, Connectivity and Interoperability Impact
TABLE 29: U.S. Personalized Diabetes Care Devices Market: Application & Innovation Landscape
TABLE 30: U.S. Personalized Diabetes Care Devices Market: FDA Regulatory Framework Analysis
TABLE 31: U.S. Personalized Diabetes Care Devices Market: CMS Reimbursement and Coverage Landscape
TABLE 32: U.S. Personalized Diabetes Care Devices Market: Cybersecurity, HIPAA and Patient Data Governance
TABLE 33: U.S. Personalized Diabetes Care Devices Market: Import/Export Restrictions & Tariff Impact
TABLE 34: U.S. Personalized Diabetes Care Devices Market: Government Diabetes Initiatives and Public Health Programs
TABLE 35: U.S. Personalized Diabetes Care Devices Market: Geopolitical and Semiconductor Supply Risk Impact
TABLE 36: U.S. Personalized Diabetes Care Devices Market: Payer and Health System Diabetes Technology Evaluation Framework
TABLE 37: U.S. Personalized Diabetes Care Devices Market: Product Category Snapshot, 2025
TABLE 38: Segment Dashboard; Definition and Scope, by Product Category
TABLE 39: U.S. Personalized Diabetes Care Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 40: U.S. Personalized Diabetes Care Devices Market: Segment Share Analysis, by Product Category, 2025 & 2035 (%)
TABLE 41: Continuous Glucose Monitoring and Personalized Biosensor Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 42: Automated Insulin Delivery Systems and Connected Insulin Pumps Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 43: Smart Insulin Pens and Connected Injection Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 44: Connected Blood Glucose Monitoring Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 45: Implantable and Adjunct Personalized Diabetes Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 46: U.S. Personalized Diabetes Care Devices Market: Application Snapshot, 2025
TABLE 47: Segment Dashboard; Definition and Scope, by Application
TABLE 48: U.S. Personalized Diabetes Care Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 49: U.S. Personalized Diabetes Care Devices Market: Segment Share Analysis, by Application, 2025 & 2035 (%)
TABLE 50: Type 1 Diabetes Management Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 51: Insulin-Requiring Type 2 Diabetes Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 52: Non-Insulin-Treated Type 2 Diabetes Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 53: Gestational and Pregnancy-Associated Diabetes Management Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 54: Secondary, Complex and High-Risk Diabetes Management Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 55: U.S. Personalized Diabetes Care Devices Market: End User Snapshot, 2025
TABLE 56: Segment Dashboard; Definition and Scope, by End User
TABLE 57: U.S. Personalized Diabetes Care Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 58: U.S. Personalized Diabetes Care Devices Market: Segment Share Analysis, by End User, 2025 & 2035 (%)
TABLE 59: Patients and Home Users Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 60: Endocrinology and Diabetes Specialty Clinics Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 61: Hospitals and Integrated Health Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 62: Primary Care and Multispecialty Practices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 63: Remote Diabetes Management and Home Healthcare Providers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 64: U.S. Personalized Diabetes Care Devices Market: Technology Type Snapshot, 2025
TABLE 65: Segment Dashboard; Definition and Scope, by Technology Type
TABLE 66: U.S. Personalized Diabetes Care Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 67: U.S. Personalized Diabetes Care Devices Market: Segment Share Analysis, by Technology Type, 2025 & 2035 (%)
TABLE 68: Real-Time Continuous Glucose Monitoring Technology Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 69: Intermittently Scanned and Consumer-Accessible Glucose Sensing Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 70: Automated and Adaptive Insulin-Control Technology Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 71: Connected Injection and Dose-Tracking Technology Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 72: AI-Enabled, Predictive and Interoperable Device Ecosystems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 73: U.S. Personalized Diabetes Care Devices Market: Regional Snapshot, 2025
TABLE 74: Segment Dashboard; Definition and Scope, by Geography
TABLE 75: U.S. Personalized Diabetes Care Devices Market, by Geography, 2021–2035 (US$ Billion)
TABLE 76: U.S. Personalized Diabetes Care Devices Market: Regional Share Analysis, 2025 & 2035 (%)
TABLE 77: U.S. Personalized Diabetes Care Devices Market: Regional Diabetes Burden and Eligible Patient Population Analysis
TABLE 78: U.S. Personalized Diabetes Care Devices Market: Regional CGM, Insulin Pump and AID Penetration Analysis
TABLE 79: U.S. Personalized Diabetes Care Devices Market: Regional Reimbursement, Payer Coverage and Device Access Dynamics
TABLE 80: West Region U.S. Personalized Diabetes Care Devices Market: Regional Overview and Trends
TABLE 81: West Region U.S. Personalized Diabetes Care Devices Market: Key Manufacturers and Market Access Ecosystem
TABLE 82: West Region U.S. Personalized Diabetes Care Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 83: West Region U.S. Personalized Diabetes Care Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 84: West Region U.S. Personalized Diabetes Care Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 85: West Region U.S. Personalized Diabetes Care Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 86: West Region U.S. Personalized Diabetes Care Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 87: West Region U.S. Personalized Diabetes Care Devices Market: Reimbursement, Distribution and Adoption Dynamics
TABLE 88: California Personalized Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
TABLE 89: Washington Personalized Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
TABLE 90: Arizona Personalized Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
TABLE 91: Colorado Personalized Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
TABLE 92: Oregon Personalized Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
TABLE 93: Utah Personalized Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
TABLE 94: Nevada Personalized Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
TABLE 95: New Mexico Personalized Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
TABLE 96: Idaho Personalized Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
TABLE 97: Montana Personalized Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
TABLE 98: Wyoming Personalized Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
TABLE 99: Alaska Personalized Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
TABLE 100: Hawaii Personalized Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
TABLE 101: Northeast Region U.S. Personalized Diabetes Care Devices Market: Regional Overview and Trends
TABLE 102: Northeast Region U.S. Personalized Diabetes Care Devices Market: Key Manufacturers and Market Access Ecosystem
TABLE 103: Northeast Region U.S. Personalized Diabetes Care Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 104: Northeast Region U.S. Personalized Diabetes Care Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 105: Northeast Region U.S. Personalized Diabetes Care Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 106: Northeast Region U.S. Personalized Diabetes Care Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 107: Northeast Region U.S. Personalized Diabetes Care Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 108: Northeast Region U.S. Personalized Diabetes Care Devices Market: Reimbursement, Distribution and Adoption Dynamics
TABLE 109: New York Personalized Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
TABLE 110: Massachusetts Personalized Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
TABLE 111: New Jersey Personalized Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
TABLE 112: Pennsylvania Personalized Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
TABLE 113: Connecticut Personalized Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
TABLE 114: Maine Personalized Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
TABLE 115: Vermont Personalized Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
TABLE 116: New Hampshire Personalized Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
TABLE 117: Rhode Island Personalized Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
TABLE 118: Delaware Personalized Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
TABLE 119: South Region U.S. Personalized Diabetes Care Devices Market: Regional Overview and Trends
TABLE 120: South Region U.S. Personalized Diabetes Care Devices Market: Key Manufacturers and Market Access Ecosystem
TABLE 121: South Region U.S. Personalized Diabetes Care Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 122: South Region U.S. Personalized Diabetes Care Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 123: South Region U.S. Personalized Diabetes Care Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 124: South Region U.S. Personalized Diabetes Care Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 125: South Region U.S. Personalized Diabetes Care Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 126: South Region U.S. Personalized Diabetes Care Devices Market: Reimbursement, Distribution and Adoption Dynamics
TABLE 127: Texas Personalized Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
TABLE 128: Florida Personalized Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
TABLE 129: Georgia Personalized Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
TABLE 130: North Carolina Personalized Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
TABLE 131: Tennessee Personalized Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
TABLE 132: South Carolina Personalized Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
TABLE 133: Alabama Personalized Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
TABLE 134: Mississippi Personalized Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
TABLE 135: Louisiana Personalized Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
TABLE 136: Arkansas Personalized Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
TABLE 137: Kentucky Personalized Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
TABLE 138: Oklahoma Personalized Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
TABLE 139: Virginia Personalized Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
TABLE 140: Maryland Personalized Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
TABLE 141: West Virginia Personalized Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
TABLE 142: Midwest Region U.S. Personalized Diabetes Care Devices Market: Regional Overview and Trends
TABLE 143: Midwest Region U.S. Personalized Diabetes Care Devices Market: Key Manufacturers and Market Access Ecosystem
TABLE 144: Midwest Region U.S. Personalized Diabetes Care Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 145: Midwest Region U.S. Personalized Diabetes Care Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 146: Midwest Region U.S. Personalized Diabetes Care Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 147: Midwest Region U.S. Personalized Diabetes Care Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 148: Midwest Region U.S. Personalized Diabetes Care Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 149: Midwest Region U.S. Personalized Diabetes Care Devices Market: Reimbursement, Distribution and Adoption Dynamics
TABLE 150: Illinois Personalized Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
TABLE 151: Ohio Personalized Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
TABLE 152: Michigan Personalized Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
TABLE 153: Minnesota Personalized Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
TABLE 154: Indiana Personalized Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
TABLE 155: Wisconsin Personalized Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
TABLE 156: Missouri Personalized Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
TABLE 157: Iowa Personalized Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
TABLE 158: Kansas Personalized Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
TABLE 159: Nebraska Personalized Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
TABLE 160: North Dakota Personalized Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
TABLE 161: South Dakota Personalized Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
TABLE 162: U.S. Personalized Diabetes Care Devices Market: Competitive Landscape Snapshot, 2025
TABLE 163: U.S. Personalized Diabetes Care Devices Market: Key Company Market Share Analysis, 2025
TABLE 164: U.S. Personalized Diabetes Care Devices Market: Company Positioning Matrix
TABLE 165: U.S. Personalized Diabetes Care Devices Market: Competitive Benchmarking Matrix
TABLE 166: U.S. Personalized Diabetes Care Devices Market: Product Portfolio and Interoperability Benchmarking of Key Players
TABLE 167: U.S. Personalized Diabetes Care Devices Market: Strategic Developments, Partnerships, M&A and Product Launches
TABLE 168: Abbott Diabetes Care: Company Profile
TABLE 169: Dexcom, Inc.: Company Profile
TABLE 170: Medtronic Diabetes: Company Profile
TABLE 171: Insulet Corporation: Company Profile
TABLE 172: Tandem Diabetes Care, Inc.: Company Profile
TABLE 173: LifeScan, Inc.: Company Profile
TABLE 174: Roche Diabetes Care: Company Profile
TABLE 175: Ascensia Diabetes Care: Company Profile
TABLE 176: Senseonics Holdings, Inc.: Company Profile
TABLE 177: Beta Bionics, Inc.: Company Profile
TABLE 178: Sequel Med Tech: Company Profile
TABLE 179: embecta Corp.: Company Profile
TABLE 180: Novo Nordisk: Company Profile
TABLE 181: Eli Lilly and Company: Company Profile
TABLE 182: CeQur Corporation: Company Profile
TABLE 183: AgaMatrix, Inc.: Company Profile
TABLE 184: Trividia Health, Inc.: Company Profile
TABLE 185: i-SENS, Inc.: Company Profile
TABLE 186: DarioHealth Corp.: Company Profile
TABLE 187: Glooko, Inc.: Company Profile
TABLE 188: Teladoc Health / Livongo: Company Profile
TABLE 189: Smart Meter LLC: Company Profile
TABLE 190: FORA Care: Company Profile
TABLE 191: Prodigy Diabetes Care: Company Profile
TABLE 192: Modular Medical, Inc.: Company Profile
TABLE 193: U.S. Personalized Diabetes Care Devices Market: Future Market Scenario Analysis, 2026–2035
TABLE 194: U.S. Personalized Diabetes Care Devices Market: Disruptive Technologies Impact Matrix
TABLE 195: U.S. Personalized Diabetes Care Devices Market: Emerging Business Trends
TABLE 196: U.S. Personalized Diabetes Care Devices Market: Standalone Devices to Personalized Ecosystems Transition
TABLE 197: U.S. Personalized Diabetes Care Devices Market: Type 2 Diabetes Advanced Device Expansion Opportunity
TABLE 198: U.S. Personalized Diabetes Care Devices Market: Pharmacy and OTC Distribution Evolution
TABLE 199: U.S. Personalized Diabetes Care Devices Market: Business Opportunities for Startups and Existing Players
TABLE 200: U.S. Personalized Diabetes Care Devices Market: Investment Prioritization Matrix
TABLE 201: U.S. Personalized Diabetes Care Devices Market: Technology Adoption Roadmap, 2026–2035
TABLE 202: U.S. Personalized Diabetes Care Devices Market: Strategic Recommendations for Diabetes Device Manufacturers
TABLE 203: U.S. Personalized Diabetes Care Devices Market: Strategic Recommendations for Hospitals and Endocrinology Networks
TABLE 204: U.S. Personalized Diabetes Care Devices Market: Strategic Recommendations for Medicare, Medicaid and Commercial Payers
TABLE 205: U.S. Personalized Diabetes Care Devices Market: Strategic Recommendations for Investors and Private Equity Firms
TABLE 206: U.S. Personalized Diabetes Care Devices Market: Strategic Recommendations for Pharmacies, DME Suppliers and Distributors
TABLE 207: U.S. Personalized Diabetes Care Devices Market: Strategic Recommendations for Virtual Diabetes Management Providers
TABLE 208: U.S. Personalized Diabetes Care Devices Market: Strategic Recommendations for New Entrants and Startups
TABLE 209: U.S. Personalized Diabetes Care Devices Market: Go-to-Market Strategy Considerations
TABLE 210: U.S. Personalized Diabetes Care Devices Market: Product Positioning and Portfolio Expansion Guidance
TABLE 211: U.S. Personalized Diabetes Care Devices Market: High-Priority U.S. State Market Entry Strategy
TABLE 212: U.S. Personalized Diabetes Care Devices Market: Scope Limitation
TABLE 213: U.S. Personalized Diabetes Care Devices Market: Data Use Limitation
TABLE 214: U.S. Personalized Diabetes Care Devices Market: Forecasting Limitation
TABLE 215: U.S. Personalized Diabetes Care Devices Market: Legal Disclaimer
TABLE 216: U.S. Personalized Diabetes Care Devices Market: Third-Party Data Disclaimer
TABLE 217: U.S. Personalized Diabetes Care Devices Market: Market Modeling and Estimate Disclaimer

List of Figures

FIGURE 1: U.S. Personalized Diabetes Care Devices Market Segmentation
FIGURE 2: Market Research Methodology
FIGURE 3: Value Chain Analysis
FIGURE 4: Supply Chain Analysis
FIGURE 5: PESTEL Analysis
FIGURE 6: Porter’s Five Forces Analysis
FIGURE 7: Market Attractiveness Analysis
FIGURE 8: Market Dynamics
FIGURE 9: Innovation & Patent Landscape, 2021–2025
FIGURE 10: Clinical Workflow Economics Framework
FIGURE 11: Patient Lifetime Device Economics Framework
FIGURE 12: Payer and Health System Diabetes Technology Evaluation Framework
FIGURE 13: U.S. Personalized Diabetes Care Devices Market Size, Historical Trend Analysis, 2021–2024 (US$ Billion)
FIGURE 14: U.S. Personalized Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2026–2035 (US$ Billion)
FIGURE 15: U.S. Personalized Diabetes Care Devices Market Year-wise Growth Curve, 2021–2035
FIGURE 16: Product Category Segment Market Share Analysis, 2025 & 2035
FIGURE 17: Product Category Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 18: Continuous Glucose Monitoring and Personalized Biosensor Systems Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 19: Automated Insulin Delivery Systems and Connected Insulin Pumps Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 20: Smart Insulin Pens and Connected Injection Systems Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 21: Connected Blood Glucose Monitoring Systems Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 22: Implantable and Adjunct Personalized Diabetes Devices Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 23: Application Segment Market Share Analysis, 2025 & 2035
FIGURE 24: Application Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 25: Type 1 Diabetes Management Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 26: Insulin-Requiring Type 2 Diabetes Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 27: Non-Insulin-Treated Type 2 Diabetes Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 28: Gestational and Pregnancy-Associated Diabetes Management Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 29: Secondary, Complex and High-Risk Diabetes Management Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 30: End User Segment Market Share Analysis, 2025 & 2035
FIGURE 31: End User Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 32: Patients and Home Users Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 33: Endocrinology and Diabetes Specialty Clinics Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 34: Hospitals and Integrated Health Systems Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 35: Primary Care and Multispecialty Practices Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 36: Remote Diabetes Management and Home Healthcare Providers Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 37: Technology Type Segment Market Share Analysis, 2025 & 2035
FIGURE 38: Technology Type Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 39: Real-Time Continuous Glucose Monitoring Technology Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 40: Intermittently Scanned and Consumer-Accessible Glucose Sensing Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 41: Automated and Adaptive Insulin-Control Technology Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 42: Connected Injection and Dose-Tracking Technology Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 43: AI-Enabled, Predictive and Interoperable Device Ecosystems Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 44: Regional Segment Market Share Analysis, 2025 & 2035
FIGURE 45: Regional Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 46: Regional Diabetes Burden and Eligible Patient Population Comparison
FIGURE 47: Regional CGM, Insulin Pump and AID Penetration Comparison
FIGURE 48: West Region U.S. Personalized Diabetes Care Devices Market Share and Leading Players, 2025
FIGURE 49: West Region Market Share Analysis by State, 2025
FIGURE 50: West Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 51: California Personalized Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 52: Washington Personalized Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 53: Arizona Personalized Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 54: Colorado Personalized Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 55: Oregon Personalized Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 56: Utah Personalized Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 57: Nevada Personalized Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 58: New Mexico Personalized Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 59: Idaho Personalized Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 60: Montana Personalized Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 61: Wyoming Personalized Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 62: Alaska Personalized Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 63: Hawaii Personalized Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 64: Northeast Region U.S. Personalized Diabetes Care Devices Market Share and Leading Players, 2025
FIGURE 65: Northeast Region Market Share Analysis by State, 2025
FIGURE 66: Northeast Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 67: New York Personalized Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 68: Massachusetts Personalized Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 69: New Jersey Personalized Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 70: Pennsylvania Personalized Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 71: Connecticut Personalized Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 72: Maine Personalized Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 73: Vermont Personalized Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 74: New Hampshire Personalized Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 75: Rhode Island Personalized Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 76: Delaware Personalized Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 77: South Region U.S. Personalized Diabetes Care Devices Market Share and Leading Players, 2025
FIGURE 78: South Region Market Share Analysis by State, 2025
FIGURE 79: South Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 80: Texas Personalized Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 81: Florida Personalized Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 82: Georgia Personalized Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 83: North Carolina Personalized Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 84: Tennessee Personalized Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 85: South Carolina Personalized Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 86: Alabama Personalized Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 87: Mississippi Personalized Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 88: Louisiana Personalized Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 89: Arkansas Personalized Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 90: Kentucky Personalized Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 91: Oklahoma Personalized Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 92: Virginia Personalized Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 93: Maryland Personalized Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 94: West Virginia Personalized Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 95: Midwest Region U.S. Personalized Diabetes Care Devices Market Share and Leading Players, 2025
FIGURE 96: Midwest Region Market Share Analysis by State, 2025
FIGURE 97: Midwest Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 98: Illinois Personalized Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 99: Ohio Personalized Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 100: Michigan Personalized Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 101: Minnesota Personalized Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 102: Indiana Personalized Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 103: Wisconsin Personalized Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 104: Missouri Personalized Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 105: Iowa Personalized Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 106: Kansas Personalized Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 107: Nebraska Personalized Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 108: North Dakota Personalized Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 109: South Dakota Personalized Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 110: Competitive Landscape; Key Company Market Share Analysis, 2025
FIGURE 111: Company Positioning Matrix
FIGURE 112: Key Player Product Portfolio Benchmarking
FIGURE 113: CGM and Automated Insulin Delivery Interoperability Benchmarking
FIGURE 114: Strategic Developments, Partnerships, M&A and Product Launches
FIGURE 115: Personalized Diabetes Device Innovation Roadmap
FIGURE 116: Next-Generation Long-Wear CGM Adoption Roadmap
FIGURE 117: Automated Insulin Delivery Expansion Opportunity Map
FIGURE 118: OTC and Consumer-Accessible Glucose Sensing Growth Roadmap
FIGURE 119: Smart Insulin Injection and Dose Automation Roadmap
FIGURE 120: AI-Assisted Predictive Diabetes Management Opportunity Map
FIGURE 121: Future Market Scenario Analysis, 2026–2035
FIGURE 122: Disruptive Technologies Impact Matrix
FIGURE 123: Emerging Business Trends Matrix
FIGURE 124: Investment Prioritization Matrix
FIGURE 125: Technology Adoption Roadmap, 2026–2035
FIGURE 126: Strategic Growth Roadmap for U.S. Personalized Diabetes Device Companies
FIGURE 127: Go-to-Market Strategy Framework
FIGURE 128: Product Positioning and Portfolio Expansion Framework
FIGURE 129: High-Priority U.S. State Market Entry Framework
FIGURE 130: Report Scope and Disclaimer Framework